WASHINGTON, Sept. 16 /PRNewswire/ — CID s.r.l., a European
company leader in interventional medicine, will update
interventional cardiologists on the status of their revolutionary
drug eluting stent technology during The Drug Eluting Stent (DES)
Summit at TCT 2010, Washington, DC on Wednesday, September 22,
2010. The lecture, entitled “Status of the CID Cre8
polymer-free DES program”, will be delivered by Alexandre Abizaid,
MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao
Paulo Brazil, and will be part of the session “The Next Generation
DES, Polymer-Free”.
Some of the highlights of the presentation will include an
exploration of the clinical benefits of CID’s Abluminal Reservoir
Technology (ART) and drug delivery technology. By surrounding
molecules of drug with amphiphilic carriers and embedding them into
reservoirs on the stent’s outer surface, CID drug-eluting stents
are able to deliver drug to the coronary arteries without using any
polymers, which can cause serious complications in patients.
CID’s unique ART system with its amphiphilic carrier is more
physiological and patients who receive these stents are less likely
to have inflammation and thrombosis within their coronary arteries.
Moreover CID DES technology features an integral Bio-Inducer
Surface (BIS) which implies less medication to prevent blood
clotting after the stent has been deployed for enhanced safety.
Commenting on the innovative technology in its new Cre8 DES,
Franco Vallana, Chief Executive Officer of CID s.r.l. said, “We
have always known that the more the stent and the drug delivery
system are designed and developed to harmonize with the human body,
the better the short- and long-term results will be. Combining ART
with our innovative drug formulation with amphiphilic carrier into
a completely polymer-free stent will allow doctors to provide their
patients with stents that are more physiological and complement the
body’s natural systems.” </
‘/>”/>
